Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Calidi Biotherapeutics, Inc

< Previous 1 2 Next >
News headline image
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
Tickers LEGN RARE
News headline image
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Provides Required NYSE American Disclosure
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Announces Proposed Public Offering
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.